February 28, 2007 – Xoma extended its partnership with Takeda to include more antibodies and making it worth as much as $230 million; Avanir said the FDA will require another clinical trial for approval of Zenvia; Accentia acquired worldwide rights to Revimmune, a treatment for autoimmune diseases; Nanogen received four patents for biomarkers; Targeted Genetics reported its HIV vaccine is safe and well-tolerated; Salix bought Pepcid and Diuril Oral Suspension from Merck; Regeneron presented data showing its Interleukin-1 (IL-1) trap was effective and safe; Human Genome Sciences said Albuferon was as effective as interferon for hepatitis; Abbott received approval to market Humira for Crohn’s disease; and EnoCeutics, a Canadian company developing hormone therapies for breast cancer, filed for an IPO. The Centient Biotech 200™ added on 1 point to end at 3930. More details...
